Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03782038 · ClinicalTrials.gov registry record · NA
Study to Evaluate the Efficacy of a Micro Coring Device for the Treatment of Scars of the Cytrellis Micro-Coring Device for the Treatment of Scars
A NA study, sponsored by Cytrellis Biosystems.
- Recruiting
- Registry status
- NA
- Development phase
- 30
- Enrollment target
NCT03782038: Recruiting NA study, sponsored by Cytrellis Biosystems.
NCT03782038 is a NA study that is actively recruiting participants, run by Cytrellis Biosystems. The registered enrollment target is 30 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03782038, a NA study, is actively recruiting participants, sponsored by Cytrellis Biosystems.
- RECRUITING
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
Study Summary
A study to evaluate the safety and effectiveness of a micro coring device for the treatment of scars.
Primary Outcome
Assessing the improvement in the aesthetic appearance of the subject based on the POSAS scale comparing baseline to 6 months post last treatment. Parameters of vascularity, pigmentation, thickness, relief, and pliability, range from 1 to 10. normal skin =1; worst scar imaginable =10.
Interventions
- DEVICE MCD
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2018-09-13 |
| Est. Completion | 2019-11-21 |
| Phase | NA |
What NCT03782038 shows while recruiting
NCT03782038 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 1 intervention - of which MCD is the first listed.
NCT03782038 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03782038 about?
NCT03782038 is a clinical study titled "Study to Evaluate the Efficacy of a Micro Coring Device for the Treatment of Scars of the Cytrellis Micro-Coring Device for the Treatment of Scars". A study to evaluate the safety and effectiveness of a micro coring device for the treatment of scars.
What is the current status of trial NCT03782038?
This trial is currently recruiting. It is a NA study. The enrollment target is 30 participants. The study started on 2018-09-13. Estimated completion is 2019-11-21.
What interventions are being tested in trial NCT03782038?
The interventions under investigation include: MCD (DEVICE).
Who is sponsoring clinical trial NCT03782038?
This trial is sponsored by Cytrellis Biosystems, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03782038's enrollment target sits among peer trials
30 1593rd of 2000 higher than 299 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI